Abstract:Background: Clinical assays for the assessment of the human epidermal growth factor receptor-2 (HER2) status in breast cancer include immunohistochemistry (IHC) and in situ hybridization (ISH), both of which have limitations. Recent studies have suggested that a more quantitative approach to the measurement of HER2 protein expression may improve specificity in selecting patients for HER-2 targeted therapy. In the current study, we have used HER2 expression in breast cancer cell lines and clinical samples as a model to explore the potential utility of a novel immunodetection technique, using streptavidin coated Phosphor Integrated Dot fluorescent nanoparticles (PID), which can be quantitatively measured using computer analysis. Methods: The expression of HER2 protein in cell lines was evaluated with antibody-binding capacity using fluorescence-activated cell sorting (FACS) for comparison with PID measurements to test for correlations with existing quantitative protein analysis methodologies. Various other analytic validation tests were also performed, including accuracy, precision, sensitivity, robustness and reproducibility. A methods comparison study investigated correlations between PID versus IHC and ISH in clinical samples. Lastly, we measured HER2 protein expression using PID in the pretreatment biopsies from 34 HER2-positive carcinomas that had undergone neoadjuvant trastuzumab-based chemotherapy. Results: In the analytic validation, PID HER2 measurements showed a strong linear correlation with FACS analysis in breast cell lines, and demonstrated significant correlations with all aspects of precision, sensitivity, robustness and reproducibility. PID also showed strong correlations with conventional HER2 testing methodologies (IHC and ISH). In the neoadjuvant study, patients with a pathologic complete response (pCR) had a significantly higher PID score compared with patients who did not achieve a pCR (p = 0.011), and was significantly correlated to residual cancer burden (RCB) class (p = 0.026, R2 = 0.9975). Conclusions: Analytic testing of PID showed that it may be a viable testing methodology that could offer advantages over other experimental or conventional biomarker diagnostic methodologies. Our data also suggests that PID quantitation of HER2 protein may offer an improvement over conventional HER2 testing in the selection of patients who will be the most likely to benefit from HER2-targeted therapy. Further studies with a larger cohort are warranted.

Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer

Medical image segmentation to estimate HER2 gene status in breast cancer

Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice

In the use of artificial intelligence and hyperspectral imaging in digital pathology for breast cancer cell identification

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

Fluorescence In Situ Hybridization (FISH) for the Characterization and Monitoring of Primary Cultures from Human Tumors

Automated Quantification of HER2 Amplification Levels Using Deep Learning

Analysis of Cancer Marker in Tissues with Hadamard Transform Fluorescence Spectral Microscopic Imaging.

Application of multispectral imaging in quantitative immunohistochemistry study of breast cancer: a comparative study

Image analysis for bright-field HER2 in situ hybridization: validation for clinical use

Detecting EGFR gene amplification using a fluorescence in situ hybridization platform based on digital microfluidics

Quantum Dots-Based Immunofluorescence Technology for the Quantitative Determination of Her2 Expression in Breast Cancer

Towards Real-Time Hyperspectral Multi-Image Super-Resolution Reconstruction Applied to Histological Samples

A Comparative Study of the Methods of Fluorescence in Situs Hybridization and Immunohistochemistry in Detecting HER-2 in Breast Cancer Tissues

A Robust Approach to Locate HER2 and CEN17 Signals in Varied FISH Images

High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers

Apply dual-color fluorescent in situ hybridization for detection of Her-2 gene in breast carcinoma paraffin section

Multispectral Fluorescence Imaging for Tumor Detection and Molecular Biology

Fluorescence In-situ Hybridization (FISH) and Its Application in Oncology

Harnessing molecular probes for imaging of human epidermal growth factor receptor (HER) family